SET domain-containing 5 is a potential prognostic biomarker that promotes esophageal squamous cell carcinoma stemness.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ physiology
Disease Progression
Esophageal Neoplasms
/ diagnosis
Esophageal Squamous Cell Carcinoma
/ diagnosis
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Male
Methyltransferases
/ physiology
Middle Aged
Neoplastic Stem Cells
/ drug effects
Prognosis
RNA, Small Interfering
/ pharmacology
Tumor Cells, Cultured
Cancer stemness
Esophageal squamous cell carcinoma
Prognosis
SETD5
Journal
Experimental cell research
ISSN: 1090-2422
Titre abrégé: Exp Cell Res
Pays: United States
ID NLM: 0373226
Informations de publication
Date de publication:
01 04 2020
01 04 2020
Historique:
received:
21
11
2019
revised:
20
01
2020
accepted:
21
01
2020
pubmed:
26
1
2020
medline:
18
11
2020
entrez:
26
1
2020
Statut:
ppublish
Résumé
SET domain-containing 5 (SETD5) is an uncharacterized member of the protein lysine methyltransferase family. Although it was reported that SETD5 gene mutations are associated with the several types of human cancer, its functional role in esophageal squamous cell carcinoma (ESCC) progression has not been fully elucidated. In the present study, we used tissue samples from 147 patients with ESCC and ESCC cell lines to determine the clinicopathological significance of SETD5 in ESCC and its effects on ESCC stemness. We performed immunohistochemical staining, immunofluorescence imaging, and tumor sphere formation, colony formation, flow cytometry, wound healing, Transwell, and western blotting assays. SETD5 expression was upregulated in ESCC tissue and associated with primary tumor (pT) stage, clinical stage, lymph node metastasis, shorter overall survival rate, and disease-free survival rate. Cox regression analyses indicated that SETD5 is an independent poor prognostic factor of ESCC. In addition, SETD5 expression was correlated with cancer stemness-related protein, hypoxia-inducible factor-1α (HIF-1α), and CD68 expression. Moreover, immunofluorescence analysis revealed that SETD5 was co-localized with CD44 and SOX2 in TE10 and TE11 cells and that exposing cells to cobalt chloride increased HIF-1α, SETD5, and stemness-related protein expression in a time-dependent manner. Furthermore, SETD5 expression was significantly correlated with the expression of cell cycle-related genes and PI3K/Akt signaling pathway-related proteins. Finally, knocking down SETD5 downregulated the expression of stemness-related and PI3K/Akt signaling pathway proteins, while inhibiting tumor spheroid formation, cell proliferation, migration, and invasion in ESCC cells. These results indicate that SETD5 expression is associated with cancer stemness and that SETD5 is a potential prognostic biomarker and therapeutic target for ESCC.
Identifiants
pubmed: 31981592
pii: S0014-4827(20)30055-0
doi: 10.1016/j.yexcr.2020.111861
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
RNA, Small Interfering
0
Methyltransferases
EC 2.1.1.-
SETD5 protein, human
EC 2.1.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
111861Informations de copyright
Copyright © 2020. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors state that they have no conflicts of interest.